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Abstract 
Background: The incidence of idiopathic pulmonary fibrosis (IPF) and mortality related to the disease have 
steadily increased in recent years. The risk of cancer is approximately eight times higher in IPF patients than in 
the general population. The purpose of this study is to determine whether the severity of IPF is related to the 
time interval between IPF diagnosis and lung cancer diagnosis and to the stage of lung cancer at diagnosis. 
Methods: In this retrospective cohort study, we reviewed the medical records of patients with lung cancer 
after IPF diagnosis from two tertiary hospitals in South Korea between 2003 and 2018. We identified 61 
patients diagnosed with lung cancer at least 3 months after being diagnosed with IPF. 
Results: The included patients had a mean age of 71.0 years, and all but one were men (98.4%). The interval 
between IPF diagnosis and lung cancer diagnosis was not related to the gender-age-physiology (GAP) stage 
(p=0.662). However, in cox proportional hazard models, a higher GAP stage was significantly correlated with 
an advanced lung cancer stage (odds ratio 11.1, p=0.003). 
Conclusions: The lung cancer stage at diagnosis was higher in patients with a higher GAP stage than in those 
with a lower GAP stage. Physicians should consider implementing more frequent surveillance with computed 
tomography scans for patients with advanced IPF. 
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Introduction 
The incidence of idiopathic pulmonary fibrosis 
(IPF), a debilitating fibrotic lung disease of unknown 
origin, is steadily increasing, as is the mortality 
associated with the condition [1]. The prognosis of 
patients with IPF is poor, and there is no curative 
treatment. The median survival time following the 
diagnosis is approximately 3 years [2]. Although the 
causes of IPF remain unknown, some risk factors have 
been identified, including advanced age; smoking; 
and inhalation of stone, metal, wood, and organic 
dust [3]. IPF and lung cancer (LC) share risk factors 
(e.g., smoking and advanced age), and pulmonary 
fibrosis itself is a risk factor for LC [4-7]. The relative 
risk of IPF patients developing LC is approximately 
eight times higher than that of the general population 
[8], and the reported prevalence of LC in patients with 
IPF ranges from 2.7% to 31.3% [6, 9]. The incidence of 
LC also increases with advancement in the clinical 
course of IPF; the cumulative incidence at 10 years of 
follow-up exceeds 50% [9-11]. 
Pulmonary fibrosis and LC also share multiple 
genetic, molecular, and cellular processes that 
predispose patients to the diseases [4, 12]. Although 
the precise properties of fibrosis that lead to the 
development of carcinoma are unknown, one 








lymphatic obstruction, which results in a local 
increase of potentially carcinogenic material [7]. 
Takahashi et al. [13] reported high concentrations of 
carcinoembryonic antigen (CEA) in the 
bronchoalveolar lavage fluid of patients with 
fibrosing alveolitis, particularly in patients with 
associated LC. These high CEA levels may be a 
marker of premalignant metaplasia and hyperplasia 
and may predict a greater risk of pulmonary 
carcinoma during the clinical course of pulmonary 
fibrosis [7]. This is consistent with the observed 
distribution of the severity of fibrotic lesions in 
patients with IPF, implicating that the inflammatory 
procedure and bronchiolar squamous metaplasia may 
contribute to the pathogenesis of cancer [7]. 
Considering their high incidence, mortality rates, and 
shared pathogenesis and risk factors, clarification of 
the relationship between IPF and LC and their clinical 
features is essential for establishing diagnostic and 
therapeutic strategies. 
Previous studies have highlighted the clinical 
risk factors associated with LC development in IPF 
patients and examined the clinical characteristics and 
survival of patients with both conditions (IPF-LC). 
There is abundant research on the epidemiological 
and mechanistic links between IPF and LC [14], and 
many researchers have focused on the incidence, 
location, or histologic type of the cancer [9, 15, 16]. 
However, the above-mentioned relationships make it 
likely that the more severe the IPF, the earlier the 
cancer will develop or progress to an advanced stage. 
IPF-LC patients are difficult to treat and have poorer 
clinical outcomes than patients with IPF or LC alone. 
Therefore, it is important to identify IPF-LC patients 
in early stages of the process and provide prompt 
management. However, little is known about the 
diagnostic and therapeutic management of these 
patients. Even the most recent American Thoracic 
Society/European Respiratory Society/Japanese 
Respiratory Society/Latin American Thoracic Society 
(ATS/ERS/JRS/ALAT) guidelines, updated in 2018, 
do not address this crucial issue [17]. In this study, we 
investigated whether the severity of IPF is related to 
the time interval between IPF diagnosis and LC 
diagnosis and to the stage of the cancer. 
Materials and Methods 
In this study, we reviewed medical records from 
two tertiary hospitals in South Korea. Eligible patients 
had been diagnosed with IPF between 2003 and 2018 
and diagnosed with LC at least 3 months later. Figure 
1 shows the data collection process. A total of 61 
eligible IPF patients were identified. Of these patients, 
40 had early stage LC (stages I to IIIA, limited stage of 
small cell LC) and 21 had advanced stage LC (stage 
IIIB and higher, extensive stage of small cell cancer). 
Patients’ gender-age-physiology (GAP) index scores 
were classified into stages I-III, with higher scores 
indicating greater severity [18]. Based on the gender, 
age, predicted forced vital capacity (FVC), and 
diffusing capacity of the lung for carbon monoxide 
(DLco), the GAP index assesses mortality risk levels. 
Due to the small number of patients in the GAP stage 
III group (n=5), this group was combined with the 
GAP stage II group (n=13). 
Clinical and laboratory data were collected from 
patients’ medical records. Data on age, sex, body mass 
index (BMI), smoking history, pulmonary function 
test results, underlying diseases, Eastern Cooperative 
Oncology Group (ECOG) performance status, 
histological type of cancer, date and cause of death, 
and the clinical and/or pathologic staging of LC were 
collected for all patients. Smoking history was 
categorized into three groups (never, former [a person 
who had smoked at least 100 cigarettes or cigars 
during their lifetime and who had quit smoking at the 
time of the interview], and current-smoker); 
cumulative smoking amount was calculated in 
pack-years. Overall survival time was calculated from 
the date of LC diagnosis to the date of death or last 
follow-up. Pulmonary function tests were performed 
at the time of IPF diagnosis. 
 
 
Figure 1. Patient recruitment flow chart. 




IPF was diagnosed using the criteria for the 
usual interstitial pneumonia (UIP) pattern as 
described by the ATS/ERS/JRS/ALAT [17]: 
sub-pleural, basal, predominantly reticular 
abnormality or honeycombing, with or without 
traction bronchiectasis, and the presence of a 
consistent UIP pattern. Detailed histories were 
obtained regarding patients’ IPF and serologic tests 
performed to exclude connective tissue disease. A 
chest computed tomography (CT) scan showing a 
definite UIP pattern was considered confirmatory of 
IPF. When the CT scans were not definitive for the 
presence or absence of IPF, these diagnoses were 
confirmed at each hospital by a team of specialists in 
pulmonary medicine, radiology, and pathology. 
Categorical variables were compared using 
Pearson’s chi-square test and continuous variables 
using independent sample t-test to compare baseline 
characteristics of GAP I and GAP II/III patients. 
Results for continuous variables are reported as mean 
with standard deviation, while categorical variables 
are reported as numbers and percentages. We further 
investigated the relationships between clinical 
parameters and mortality using Cox proportional 
hazard models with stepwise selection of variables 
found to be significant in the univariate regression 
analysis. As age, gender, FVC, and DLco are included 
in the GAP index, they were excluded from the 
proportional regression and hazard models. A 
p-value less than 0.05 was used to indicate statistical 
significance. All statistical analyses were performed 
using IBM SPSS Statistics (version 25.0). 
This research protocol was approved by the 
Institutional Review Board of Severance Hospital, 
South Korea (IRB No. 4-2018-0770) and the 
Institutional Review Board and Ethics Committee of 
Seoul National University Bundang Hospital (IRB No. 
B-1707/411-402). The study design was approved by 
the appropriate ethics review boards, and the 




Baseline characteristics of the study subjects are 
shown in Table 1. Patients had a median age of 71.0±
7.7 years, all but one were men (98.4%), and 54 (88.5%) 
were either past or current smokers. The cumulative 
smoking amount (pack-years) was higher among 
patients with an advanced GAP stage. Hypertension 
and diabetes mellitus were the most common 
comorbidities in the early GAP stage group, but 
tuberculosis and chronic obstructive lung disease 
(COPD) were diagnosed more frequently in the 
advanced group. 
 
Table 1. Patient baseline characteristics and comorbidities 
according to GAP stage 
Variable GAP I GAP II/III Total p-value 
Total patients, n (%) 43 (70.5) 18 (29.5) 61 (100.0)  
Age (years) 70.6 ± 8.5 72.0 ± 5.6 71.0 ± 7.7 0.524 
Sex, male (%) 42 (97.7) 18 (100.0) 60 (98.4) 0.527 
BMI, kg/m2 23.9 ± 2.4 22.6 ± 4.0 23.5 ± 3.0 0.139 
GAP score 2.7 ± 0.6 5.1 ± 1.3 3.4 ± 1.4 <0.001 
Smoking exposure, No. (%)    0.467 
Never 5 (11.6) 2 (11.1) 7 (11.5)  
Former 31 (72.1) 15 (83.3) 46 (75.4)  
Current 7 (16.3) 1 (5.6) 8 (13.1)  
Smoking amount, 
(Pack-years) 
35.6 ± 23.8 47.8 ± 39.8 39.4 ± 29.9 0.152 
FVC, % predicted 94.8 ± 15.1 75.0 ± 24.0 86.8 ± 21.3 0.004 
DLco, % predicted 74.3 ± 16.7 67.0 ± 20.9 71.0 ± 18.7 0.308 
ECOG    0.001 
0/1/2/3 10/22/6/2 4/6/4/1 14/28/10/3  
Medical history, n (%)     
Hypertension 23 (53.5) 7 (38.9) 30 (49.2) 0.298 
Diabetes mellitus 14 (32.6) 2 (11.1) 16 (26.2) 0.085 
Cardiovascular disease 2 (4.7) 2 (11.1) 4 (6.6) 0.442 
Rheumatic disease 2 (4.7) 1 (5.6) 3 (4.9) 0.883 
Prior tuberculosis 3 (7.0) 6 (33.3) 9 (14.8) 0.009 
COPD 6 (14.0) 5 (27.8) 11 (18.0) 0.204 
Other malignancy 9 (21.0) 4 (22.2) 13 (21.3) 0.748 
Overall mortality, n (%) 25 (58.1) 15 (83.3) 40 (65.6) 0.140 
Median OS, months 20.8 ± 18.3 11.1 ± 12.6 18.2 ± 17.4 0.065 
Abbreviations: GAP staging system, gender (G), age (A), forced vital capacity 
(FVC), and diffusing capacity of carbon monoxide (DLco); BMI, body mass index; 
COPD, chronic obstructive lung disease. 
Data are presented as median, interquartile range, or frequency (%). 
 
 
Table 2 shows the patients’ specific 
characteristics of LC and IPF. There was no significant 
difference between the GAP groups regarding the 
diagnostic interval between IPF and LC diagnoses 
(1445.4 days vs. 1281.1 days). Adenocarcinoma was 
the most common histology in GAP stage I patients; 
however, squamous cell carcinoma was more 
common in stage II/III patients. The most frequent 
histologic types in early-stage LC patients were 
squamous cell carcinoma (39.1%) and 
adenocarcinoma (35.4%); however, adenocarcinoma 
(32.1%), was more common than squamous cell 
carcinoma (25.0%) in advanced-stage LC patients. 
Relationship between lung cancer stage and 
GAP stage 
Table 3 shows the univariate regression results 
for associations between advanced LC stage and 
clinical factors. A higher LC stage had a significant 
negative association with BMI (odds ratio [OR]=0.793, 
95% confidence interval [CI]=0.649-0.971, p=0.025), 
but a significant positive association with higher GAP 
stage (OR =5.186, 95% CI=1.589-16.920, p=0.006). Age, 
smoking status, predicted FVC, predicted DLco, and 
IPF treatment did not significantly affect LC stage. 




Table 2. Characteristics of LC and IPF according to GAP stage 
Variable GAP I GAP II/III Total p-value 
Time from IPF to LC* 
(day) 
1445.4 ±1420.1 1281.1±983.4 1396.9±1300.5 0.662 
The number of CT 
scans§ 
2.63 (2.0, 19.0) 2.41 (2.0,7.0) 2.56 (2.0,19.0) 0.714 
Period from IPF to 
LC/CT count (day) 
626.1± 599.5 581.2±484.4 612.9±564.4 0.780 
Cancer treatment, n (%)     
Operation 23 (54.5) 3 (16.7) 26 (42.6)  
Cytotoxic chemotherapy  22 (51.2) 3 (16.7) 25 (41.0)  
Targeted/ 
Immunotherapy 
6 (14.0) 1 (5.6) 7 (11.5)  
CCRT 11 (25.6) 0 (0.0) 11 (18.0)  
Radiotherapy alone 5 (11.6) 3 (16.7) 8 (13.1)  
Conservative care 2 (4.7) 5 (27.8) 7 (11.5)  
Clinical lung cancer stage, n (%)   0.005 
I to IIIA (early) 33 (82.5) 7 (17.5) 40 (65.6)  
IIIB to IV (advanced) 10 (47.6) 11 (52.4) 21 (34.4)  
IPF treatment, n (%) 8 (18.6) 7 (38.9) 15 (24.6)  0.162 
Histologic type, n (%)    0.063 
Small cell carcinoma 10 (23.3) 4 (22.2) 14 (23.0)  
Adenocarcinoma 18 (41.9) 4 (22.2) 22 (36.1)  
Squamous cell 
carcinoma 
14 (32.6) 9 (50.0) 23 (37.7)  
Other 1 (2.3) 1 (5.6) 2 (3.3)  
Abbreviations: GAP staging system, gender (G), age (A), forced vital capacity 
(FVC), and diffusing capacity of carbon monoxide (DLco); CT, computed 
tomography; CCRT, concurrent chemoradiotherapy; ECOG, Eastern Cooperative 
Oncology Group; RT, radiotherapy; CTx, chemotherapy; OS, overall survival. 
Data are presented as median, interquartile range, or frequency (%).  
*Time from IPF to LC, time gap between diagnosis of lung cancer and diagnosis of 




Table 3. Results from the univariate logistic regression analysis of 
clinical factors associated with advanced lung cancer stage 
Variable OR 95% CI p-value 
Age (years) 1.037 0.965-1.115 0.317 
BMI, kg/m2 0.793 0.649-0.971 0.025 
Ever smoker 0.814 0.125-5.306 0.830 
FVC % predicted 0.984 0.961-1.009 0.211 
DLco % predicted 0.999 0.977-1.021 0.929 
GAP stage (Stage I vs. II/III) 5.186 1.589-16.920 0.006 
IPF treatment 0.889 0.223-3.542 0.867 
Time Gap between diagnosis of lung 
cancer and diagnosis of IPF, days 
1.000 1.000-1.001 0.514 
Abbreviations: GAP stage system, gender (G), age (A), forced vital capacity (FVC), 
and diffusing capacity of carbon monoxide (DLco); BMI, body mass index; OR, 
odds ratio; CI, confidence interval. 
 
 
Table 4 shows the relationship between LC stage 
and clinical factors in the multivariate logistic 
regression model. In the logistic regression model, the 
adjusted OR (aOR) for BMI with LC stage had 
weakened slightly (aOR=0.710, 95% CI: 0.508-0.992, 
p=0.045). However, the OR for the higher GAP stage 
group more than doubled from that of the univariate 
model (aOR=12.158, 95% CI: 1.868-79.138, p=0.009). 
Figure 2 shows the cox regression analysis of LC stage 
by GAP stage; a similar result was achieved from the 
proportional hazard model when adjusted for cancer 
histology and IPF treatment (aOR=11.121, 95% CI: 
2.311-53.532, p=0.003). 
Survival outcomes 
Overall mortality was 58.1% in the early GAP 
stage group and 83.3% in the advanced GAP stage 
group, and the mean overall survival time was 20.8±
18.3 months in the early GAP stage group and 11.1±
12.6 months in the advanced GAP stage group. Figure 
3 shows the Cox regression analysis of survival 
probability by GAP stage, with adjustments for IPF 
treatment, smoking status, BMI, and histology. There 
was a significantly lower survival rate in the 
advanced GAP stage group (aOR=2.860, 95% CI: 
1.257-6.508, p=0.012). 
Among patients with early stage LC, overall 
survival was higher for those in the GAP stage I group 
after adjustment for cancer histology, BMI, smoking 
status, and IPF treatment, although the difference was 
not significant (Figure 4A, aOR=1.613, 95% CI: 
0.502-5.184, p=0.422). However, the survival of 
patients with advanced stage LC was significantly 
higher for those in GAP stage I than in the advanced 
GAP stages (Figure 4B, aOR=10.412, 95% CI: 
1.421-76.285, p=0.021). 
Table 5 shows the causes of death in the GAP 
groups. Cancer progression was the main cause of 
death in the advanced GAP group (38.9%); however, 
pneumonia (16.3%) and AE-IPF (16.3%) were also 
dominant in the early GAP stage group. 
 
Table 4. Results from the multivariate logistic regression analysis 
of clinical factors associated with early vs. advanced lung cancer 
stage 
Variable OR 95% CI p-value 
BMI, kg/m2 0.710 0.508-0.992 0.045 
Ever smoker 0.787 0.091-6.799 0.828 
GAP stage (Stage I vs. II/III) 12.158 1.868-79.138 0.009 
IPF treatment 0.558 0.078-4.010 0.562 
Abbreviations: GAP stage system, gender (G), age (A), forced vital capacity (FVC), 
and diffusing capacity of carbon monoxide (DLco); BMI, body mass index; OR, 
odds ratio; CI, confidence interval. 
 
Table 5. Comparison of the causes of death according to GAP 
stage 
Cause of death, n (%) GAP I (n=43) GAP II/III (n=18) Total (n=61) 
Pneumonia 7 (16.3) 3 (16.7) 10 (16.4) 
RT/CTx pneumonitis 2 (4.7) 1 (5.6) 3 (4.9) 
Cancer progression 7 (16.3) 7 (38.9) 14 (23.0) 
AE-IPF 7 (16.3) 3 (16.7) 10 (16.4) 
*Other causes 2 (4.7) 1 (5.6) 3 (4.9) 
Total 25 (58.1) 15 (83.3) 40 (65.6) 
*Other causes: Subdural hemorrhage and chronic renal failure in GAP I group; 
systemic viral infection in GAP II/III group. 
Abbreviations: RT, radiotherapy; CTx, chemotherapy; AE-IPF, acute exacerbation 
of idiopathic pulmonary fibrosis. 
 
Discussion 
IPF and LC have common risk factors, and 
patients with both conditions are known to have a 




worse prognosis than patients with either condition. 
This study involved patients with LC that developed 
after the diagnosis of IPF. Our results showed that IPF 
severity is associated with the LC stage, but not the 
interval between IPF and LC diagnoses. 
The demographic and clinical characteristics of 
the patients in this study are similar to those reported 
in previous studies. Most patients were older men 
with tobacco exposure [11, 19]. Although Ozawa et al. 
[11] did not find differences in survival rates between 
IPF patients with and without LC, recent studies have 
reported worse survival outcomes among IPF-LC 
patients [9, 19, 20]. Tomassetti et al. [9] reported that 
the development of LC in IPF patients significantly 
decreased their median overall survival (IPF with LC: 
38.7 months, IPF without LC: 63.9 months; hazard 
ratio = 5.0; 95% CI: 2.91–8.57; p < 0.001). Tzouvelekis et 
al. [21] reported the median survival of IPF-LC 
patients to be 27.4 and 14.3 months from the time of 
IPF and LC diagnoses, respectively. 
In this report, we have described the differences 
in clinical features and stages of LC between patients 
with early and advanced GAP 
stages. A significant result of our 
study was the ability to establish 
an association between IPF 
severity and LC stage, showing 
that GAP stage had an 
independent, positive association 
with LC stage. This suggests that 
patients with an advanced GAP 
stage require more frequent CT 
scans than the general 
population in addition to close 
observation at their routine 
follow-ups. Even if the LC stage 
differed according to the GAP 
stage, there was no significant 
difference in the time interval 
between IPF and LC diagnoses 
(904 days in GAP stage I vs. 959 
days in GAP stage II/III). 
These two diseases share 
biological signaling pathways 
and microenvironments that 
have been shown to disrupt 
tissue architecture and lead to 
dysfunction, contributing to 
carcinogenesis and fibrosis (e.g., 
transforming growth factor beta, 
platelet-derived growth factor, 
vascular endothelial growth 
factor, and fibroblast growth 
factor) [22]. Considering the 
theory that LC developing next 
to or within fibrosis can cause 
cellular metaplasia and the 
longstanding hypothesis that the 
pathogenesis of tissue damage 
and abnormal repair are common 
processes in both IPF and LC, it is 
reasonable that patients with IPF 
are vulnerable to the 
development of cancer [19, 23]. 
Generally, the fibrotic area is 
broader in patients with an 
 
 
Figure 2. Cox regression model of lung cancer stage by GAP stage, adjusted for idiopathic pulmonary fibrosis 
treatment and histology. 
 
Figure 3. Cox regression model of survival probability by GAP stage, adjusted for IPF treatment, smoking status, body 
mass index, and histology. 




advanced GAP stage than in those with an early GAP 
stage; therefore, the malignancy would be aroused 
concomitantly in the widespread areas and result in 
higher stages of LC. 
In patients with early stage LC, the overall 
survival was higher (though not significantly) in 
patients with GAP stage I than in those with GAP 
stage II/III (Figure 4A). However, survival in patients 
with advanced LC stage differed significantly 
according to the GAP stage (Figure 4B). This suggests 
that when LC is at an advanced stage, the disease 
course could be affected by the GAP stage, which 
itself is determined by the severity of fibrosis, residual 
pulmonary functions, and age. A previous study of 
retrospective data suggested a beneficial effect of 
preoperative pirfenidone on the incidence of 
postoperative acute exacerbations in patients with 
adenocarcinoma and IPF [24]. A recent study also 
suggested that antifibrotic agents should not be 
discontinued during the diagnostic or therapeutic 
work-up of LC patients, as benefits seem to outweigh 
the risk of unfavorable outcomes [1]. Our data also 
suggest that IPF severity affects survival and that 
clinicians should consider maintaining IPF and 
anti-cancer treatments, even when the cancer is at an 
advanced stage. A consensus statement regarding the 
treatment of these patients needs to be developed. 
Conventional chemotherapy and radiotherapy 
can have deleterious effects on patients with IPF [6, 
25, 26], and optimal treatment regimens have not been 
established. Considering the high 
incidence and difficulties encountered 
in treating patients with IPF-LC, those 
with more severe pulmonary fibrosis 
are more difficult to treat because of 
the higher risk of acute exacerbation. 
The high incidence of LC and its 
impact on patient survival 
underscores the importance of 
clinicians recognizing the predictive 
factors of LC development and the 
need for thorough surveillance 
protocols. 
Although our results showed 
that fibrosis severity may affect LC 
stage, there was no clinical effect of 
IPF treatment for delaying LC 
development (OR 0.889, p=0.867, 95% 
CI=0.223-3.542). This may have been a 
reason behind the small number of 
patients undergoing IPF treatment (n= 
8 vs. 7 in both groups, respectively). A 
cohort study with a larger sample size 
is needed. 
The main strength of our study is 
that we highlighted the relationship 
between IPF severity and LC severity, 
which has rarely been studied. 
We recognize that this study did 
have several limitations: in particular, 
the small sample size and use of 
retrospective data. However, we 
collected the data from two tertiary 
care hospitals to improve their 
generalizability. Second, due to the 
study’s retrospective nature, we could 
not provide a guide for the optimal CT 
scan interval for LC surveillance in the 
different GAP groups. 
 
 
Figure 4. Cox regression model of survival probability adjusted for IPF treatment, smoking status, body mass 
index, and histology. A. Patients with early stage lung cancer by gender-age-physiology (GAP) stage. B. Patients 
with advanced stage lung cancer by GAP stage. 





To our knowledge, this study is the first to show 
a clear relationship between IPF severity and LC 
severity. In particular, we found that LC stage is 
affected by the progression of fibrosis, with higher 
GAP stages resulting in more advanced cancer stages. 
These results can provide guidance for treating IPF 
patients; more frequent checkups and CT scans are 
warranted to enable early detection of cancer 
development. Considering the high incidence of LC 
and its impact on the survival of IPF patients, frequent 
surveillance and close observation are needed from 
the time of initial IPF diagnosis. Large and 
prospective multicenter studies will be key to the 
development of protocols for the optimal 
management of patients with IPF-LC. 
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